Enalapril in patients after mitral valve replacement
Abstract
Aim. To assess enalapril effectiveness in myocardial remodeling correction among patients after mitral valve replacement.
Material and methods. In total, 54 patients (mean age 46,3±7,6 years) with isolated or prevalent mitral valve stenosis were examined. All participants underwent surgical valve disease correction. In early post-surgery period, all subjects without contraindications started enalapril therapy (2,5-20,0 mg/d). Mean follow-up lasted for 17,1±5,2 months after valve replacement. Clinical and functional status was assessed by NYHA classification and 6-minute walking stress results. Before the surgery and during dynamic follow5up, all patients underwent electrocardiography and echocardiography. Statistical analysis was performed with Statistica 6.0 software (StatSoft, Inc).
Results. Assessing post-surgery hemodynamic parameters in atrial fibrillation (AF) patients, the authors observed that enalapril therapy demonstrated more beneficial hemodynamic effects than in sinus rhythm participants. In patients with sinus rhythm, enalapril therapy significantly reduced only pulmonary artery pressure (PAP).
Conclusion. Enalapril therapy in patients after mitral valve replacement improves heart chamber size and PAP dynamics, especially in persistent AF participants.
About the Authors
O. L. Barbarash
Kemerovo State Medical Academy, Kemerovo
Russian Federation
Russian Federation
E. V. Tavlueva
Kemerovo State Medical Academy, Kemerovo
Russian Federation
Russian Federation
Yu. V. Krotikov
Scientific and Clinical Laboratory of Reconstructive Cardiovascular Surgery
Russian Federation
Russian Federation
I. N. Sizova
Scientific and Clinical Laboratory of Reconstructive Cardiovascular Surgery
Russian Federation
Russian Federation
L. S. Barbarash
Scientific and Clinical Laboratory of Reconstructive Cardiovascular Surgery
Russian Federation
Russian Federation
References
1. Бокерия Л.А., Скопин И.И., Бобриков О.А. Современный взгляд на сроки оперативного лечения приобретенных пороков сердца и его результаты. Клин мед 2003; 8: 4-10.
2. Кнышова Г.В., Бендет Я.А. Приобретенные пороки сердца. Киев 1997; 55-6.
3. Нарусов О.Ю., Скворцов А.А., Мареев В.Ю. и др. Клинические и гемодинамических эффекты дигоксина у больных с ХСН. Серд недостат 2000; 1(1): 12-8.
4. Плечев В.В., Онегов Д.В., Сурков В.А. и др. Опыт применения лозартана при коррекции легочной гипертензии у больных с пороками митрального клапана. Патол кровообр кардиохир 2002; 4: 48-51.
5. Привалов Е.В., Ершов В.И., Ермаков А.И. и др. Лечение резидуальной легочной гипертензии эналаприлом у больных, оперированных по поводу ревматических митральных пороков сердца. Клин мед 2000; 2: 40-2.
6. Carson P. Pharmacologic treatment of congestive heart failure. Clin Cardiol 1996; 19: 271-7.
7. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: resulrs of the Cooperative North Scandinavian Enalapril Survial Study (CONSENSUS). N Engl J Med 1987; 316: 1429-35.
8. Dubois D, Dubois EF. A formula to estimate the approximative surface area if height and weight are known. Arch Intern Med 1916; 17: 863-71.
9. Garg R, Yusuf S. For the collaborative group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450-6.
10. Kitabatake NА, Michitochi МD, Masato MD, et al. Nonenvasive evaluation of pulmonary hypertensior by a pulsod Doppler technique. Circulation 1983; 68: 302-9.
11. Pfeffer MA, Brounwald E, Moue LA, et al. on behalf of SAVE Investigators. The effect of captopril on mortality and morbidity in patients with left ventricular dysfunction following myocardial infarction: result of the Survival and Ventricular Enlargement (SAVE) trial. N Engl J Med 1992; 327: 669-70.
12. Nong Z, Stassen J-M, Moons L, et al. Inhibition of Tissue Angiotensin-Converting Enzyme With Quinapril Reduces Hypoxic Pulmonary Hypertension and Pulmonary Vascular Remodeling. Circulation 1996; 94: 1941-7.
Review
For citations:
Barbarash O.L., Tavlueva E.V., Krotikov Yu.V., Sizova I.N., Barbarash L.S. Enalapril in patients after mitral valve replacement. Cardiovascular Therapy and Prevention. 2007;6(4):57-62. (In Russ.)
Views:
531
Email this article 
